Clinical Trials

93 enrolled

Leukemia, Myeloid, Acute

NCT05564390 2026-04-20

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06176989 2026-04-08

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

40 enrolled

CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT06756308 2026-04-07

A Study of Enasidenib in People With T-Cell Lymphoma

25 enrolled

Lymphoid

Lymphoma, T-Cell

NCT03728335 2026-03-13

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

35 enrolled

Leukemia, Myeloid, Acute

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

50 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03383575 2026-02-17

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Classical hematologyOther hematologic neoplasm

63 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04203316 2026-01-09

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Phase 2 Active not recruiting

1 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT03744390 2025-05-18

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

68 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05401097 2025-05-14

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

125 enrolled

Leukemia, Myeloid, Acute

NCT04281498 2025-02-04

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Phase 2 Completed

6 enrolled 11 charts

Myeloid

Primary Myelofibrosis

NCT04522895 2024-09-19

IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT

Phase 2 Completed

50 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03825796 2023-09-28

CPX-351 Plus Enasidenib for Relapsed AML

2 enrolled

Leukemia, Myeloid, Acute

NCT03881735 2021-03-10

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Phase 2 Withdrawn